Search
Clinician Ordering Portal
Scientific evidence
The importance of incorporating drug-drug interactions and lifestyle factors in pharmacogenomics-guided medication management for patients with major depressive disorder in a randomized controlled trial
Sep 2023
In this study, drug-drug interactions accounted for 32% of all IDgenetix-guided drug recommendations, and lifestyle factors accounted for 11%. Incorporating these non-genetic factors in IDgenetix testing significantly impacts the number of drug recommendations and improves remission rates in patients with moderate to severe depression.
Publication: Poster at Psych Congress 2023
The tissue systems pathology-9 test provides clinically-impactful risk stratification in patients with Barrett’s esophagus: clinical experience in a multicenter cohort
Aug 2023
This study evaluated the use of the validated, commercially-available tissue systems pathology test (TissueCypher, TSP-9) to risk-stratify BE patients in a large clinical practice cohort.
Publication: Diseases of the Esophagus
31-gene expression profile testing in cutaneous melanoma and survival outcomes in a population-based analysis: A SEER collaboration
Jun 2023
Study data from Castle Biosciences' collaboration with the National Cancer Institutes SEER program registries.
Publication: JCO-PO
Abnormally pigmented lesion with uncertain malignant potential
Jun 2023
With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.
Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis
Jun 2023
Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.
Atypical melanocytic proliferation on sensitive preauricular check
Jun 2023
Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.
Multi-colored lesion with uncertain malignant potential
Jun 2023
Conflicting clinical and histopathological findings are resolved with the use of GEP test results.
Asymmetrical pigmented lesion with high clinical suspicion for melanoma
Jun 2023
A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.
Improved response and remission rates in patients receiving IDgenetix-guided medication management for major depressive disorder
May 2023
In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission compared to patients whose medication was not guided by the test
Publication: Poster at 2023 American Psychiatric Association (APA) Annual Meeting
Incorporation of the 40-gene expression profile (40-GEP) test to improve treatment decisions in high-risk cutaneous squamous cell carcinoma (cSCC) patients: case series and algorithm
May 2023
Cutaneous squamous cell carcinoma (cSCC) has become a significant public health issue due to its rapidly rising incidence and an estimated 1.8 million newly diagnosed cases annually. As with other cancers, treatment decisions for patients with cSCC are based primarily on a patient’s risk for poor outcomes.
Publication: Clinical, Cosmetic and Investigational Dermatology
A tissue systems pathology test has significant clinical utility to standardize management leading to improved health outcomes for Barrett’s esophagus patients with low-grade dysplasia
May 2023
Publication: Poster presentation (Tu1270) at DDW 2023, Chicago
A tissue systems pathology test enables standardized, risk-aligned management of patients with Barrett’s esophagus
May 2023
Publication: Poster presentation (Tu1271) at DDW 2023, Chicago